ClinicalTrials.gg
RecruitingNCT06081348CALMUpdated Jul 27, 2026

Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders

A Phase 2 interventional study of Sertraline and Placebo in Neurodevelopmental Disorders, Autism and Autism Spectrum Disorder, sponsored by Holland Bloorview Kids Rehabilitation Hospital. Recruiting at 7 sites in Canada. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Holland Bloorview Kids Rehabilitation Hospital · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.
Phase
Phase 2
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
8 Years to 17 Years
Sex
All
01

Study summary

There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs. More research is needed to confirm whether or not sertraline could help improve anxiety in children and youth with common and rare neurodevelopmental conditions. This is a pilot study, in which we plan to estimate the effect size of reduction in anxiety of sertraline vs. placebo. across rare and common neurodevelopmental disorders, and determine the best measure(s) to be used as a primary transdiagnostic outcome measure of anxiety, as well as diagnosis specific measures in future, larger-scale clinical trials of anxiety in NDDs.

02

Conditions studied

  • Neurodevelopmental Disorders
  • Autism
  • Autism Spectrum Disorder
  • Fragile X Syndrome
  • Tuberous Sclerosis
  • 22Q11 Deletion Syndrome
  • 22Q11 Deletion
  • ADHD
  • Tic Disorders
  • Tourette Syndrome
  • Tourette Syndrome in Children
  • Tourette Syndrome in Adolescence
  • ADHD - Combined Type
  • ADHD Predominantly Inattentive Type
  • ADHD, Predominantly Hyperactive - Impulsive
  • Anxiety
  • Anxiety Disorders
03

In context

Neurodevelopmental Disorders

352 studies on the registry are indexed under Neurodevelopmental Disorders; 141 are open to participants now.

This study's planned enrollment of 130 is above the median of 88 across 217 interventional studies indexed under Neurodevelopmental Disorders.

Browse Neurodevelopmental Disorders studies →

Lead sponsor

Holland Bloorview Kids Rehabilitation Hospital is the lead sponsor of 64 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Outpatients 8-17 years of age, inclusive
  2. Females of child bearing potential who are sexually active and agree to use medically acceptable throughout the study and at least one week post last dose of study drug.
  3. Meet - DSM-5 criteria for ASD, ADHD, Tic Disorders, or genetic diagnosis of Fragile X, tuberous sclerosis or 22q11 deletions.
  4. Meet DSM-5 criteria for one of the following anxiety disorders: Separation Anxiety Disorder, Social Anxiety Disorder, Agoraphobia, Generalized Anxiety Disorder, or Unspecified Anxiety Disorder, based on expert clinical interview, supported by the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS; Kaufman et al., 2016). Other specified anxiety disorder is included to account for youth with impairing anxiety symptoms who may not meet criteria for one of the other anxiety disorders.
  5. Have a Clinician's Global Impression-Severity for anxiety (CGI-S; Guy, 1976)) score ≥ 4 (moderately ill) (inter-rater reliability will be done prior to initiation of enrollment, using videotapes of interviews and vignettes)
  6. If already receiving interventions, must meet the following criteria:

    1. If receiving concomitant medications affecting behaviour, must be on a stable dose during the month prior to screening and will not electively modify ongoing medications for study duration
    2. If already receiving stable non-pharmacological behavioural interventions, have stable participation during 3 months prior to screening, and will not electively modify ongoing interventions
  7. Ability to complete assessments in English

Exclusion criteria

Exclusion Criteria:

  1. Receiving other SSRIs within four weeks of randomization (6 weeks for fluoxetine)
  2. Previous treatment with sertraline, at an adequate dose (at least 100mg for 6 weeks, or lower dose and duration if not well-tolerated), associated with no response or significant-to-the-participant side effects.
  3. Received more than 2 previous appropriate trials of SSRIs with no adequate response
  4. Pregnant females or sexually active females on inadequate
  5. Serious medical condition that, based on Investigator judgment, might interfere with the conduct of the study, confound interpretation of the study results, or endanger participant. In addition diabetic patients on medications for glycemic control will be excluded as sertraline may interfere with glycemic control.
  6. to sertraline or any components of its formulation
  7. On Monoamine Oxidase Inhibitors or pimozide (as per product monograph)
  8. On concomitant medications known to significantly increase where this would result in unacceptable risk per Investigator judgment.
  9. Known congenital QT prolongation
  10. , or C, hemophilia, abnormal blood pressure, substance abuse, immunity disorder, major depressive episode or psychosis (as required by Health Canada)
  11. Unable to tolerate venipuncture
  12. Unable to swallow capsules
  13. Enrolled in another intervention study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
130 participants (estimated)

Study arms

  • Active comparator
    Sertraline

    Drug: Sertraline

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Oral capsule (25mg, 50mg, 100mg, 200mg)

    Also known as: Sertraline Hydrochloride, Zoloft, Serotonin Reuptake Inhibitor

  • OtherPlacebo

    Oral placebo capsule

06

What researchers measure

Primary outcomes

  1. The Screen for Child Anxiety Related Emotional Disorders (SCARED) - parent version

    The SCARED is a 41-item measure of anxiety symptoms, with both child and parent versions. The parent version will be used as a primary outcome measure. The minimum overall score is 0 while the maximum overall score is 82. A score greater than or equal to 25 may indicate the presence of an Anxiety Disorder. Higher scores indicate a higher instance of anxiety symptoms while a lower score indicates a lower instance of anxiety symptoms.

    Time frame: 16 weeks

Secondary outcomes

  1. Clinical Global Impressions - Improvement Scale - Global (CGI-I)

    The CGI-I is a clinician reported scale which will be used to examine the effect of sertraline vs. placebo on measures of global function. The CGI-Improvement Scale employs a seven point (1 = very much improved to 7 = very much worse) to determine the participant's improvement in response to treatment.

    Time frame: 16 weeks

  2. Adverse events

    Adverse events as elicited by the SMURF.

    Time frame: 16 weeks

  3. Pediatric Quality of Life Inventory (PedsQL)

    The PedsQL will be used to examine the effect of sertraline vs. placebo on measures of quality of life. The PedsQL is measuring health-related quality of life (HRQOL) in 2- to 18-year-olds. The PedsQL 4.0 Generic Core Scales are multidimensional child self-report and parent-proxy report scales that have been used extensively as an outcome measure, including in ASD. We will use the parent-proxy report scale, and optionally, age-appropriate child self-report scale. Each item is is rated between a 0 (Never a problem) to 4 (Almost always a problem).

    Time frame: 16 weeks

  4. Whole blood serotonin (5-HT) assessment

    A whole blood serotonin assessment will be completed to examine the effect of sertraline vs. placebo on biomarkers of serotonin. 3mL of blood will be drawn at screening and week 16 visits for the purpose of this assessment. High performance liquid chromatography will be performed using fluorometric detection of 5-HT, tryptophan (TRP), and 5-hydroxyindole acetic acid (5-HIAA), using N-methylserotonin as an internal standard. Using this method, 5-HT intra- and inter- assay coefficients of variation are reliably less than 5% and 10%, respectively.

    Time frame: 16 weeks

  5. Clinical Global Impressions- Improvement Scale (CGI-I) focused on anxiety

    The CGI-I is a clinician reported scale which will be used to examine the effect of sertraline vs. placebo on measures of global anxiety. The CGI-Improvement Scale employs a seven point (1 = very much improved to 7 = very much worse) to determine the participant's improvement in response to treatment.

    Time frame: 16 weeks

07

Study locations

6 of 7 sites recruiting
  • Alberta Children's Hospital - University of Calgary
    Calgary, Alberta, Canada
    Recruiting
  • University of Alberta-Glenrose
    Edmonton, Alberta, Canada
    Recruiting
    • Keneizha Rubanarayana · Contactmetcoord@ualberta.ca
    • Dr. Francois Bolduc · Principal investigator
  • Dalhousie University - IWK Health Centre
    Halifax, Nova Scotia, Canada
    Active, not recruiting

    Not enrolling at this site.

  • McMaster University
    Hamilton, Ontario L8S4K1, Canada
    Recruiting
    • Lavaneyaa Sri · Contactsrisithl@mcmaster.ca · 365-833-0109
    • Dr. Elisabetta Trinari · Principal investigator
  • Queen's University
    Kingston, Ontario K7M8A6, Canada
    Recruiting
    • Stamatoula Pasvanis · Contacts.pasvanis@queensu.ca · 613-533-6000
    • Dr. Sarosh Khalid-Khan · Principal investigator
  • University of Western Ontario, Lawson Health Research Institute
    London, Ontario N6A 5W9, Canada
    Recruiting
    • Ahsan Ahmad · Contactahsan.ahmad@lhsc.on.ca · (519) 685-8500
    • Dr. Robert Nicolson · Principal investigator
  • Holland Bloorview Kids Rehabilitation Hospital
    Toronto, Ontario M4G 1R8, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: After publication

Access criteria: Through Brain Code

Data sharing details ↗ · braininstitute.ca

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2023
First posted
Oct 13, 2023
StartActual
Sep 16, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06081348
Lead sponsor
Holland Bloorview Kids Rehabilitation Hospital
Collaborators
Azrieli Foundation (Funder), Canadian Institutes of Health Research (Funder), Ontario Brain Institute (Funder), McMaster University, Western University, Queen's University, University of Alberta, Alberta Health services, St. Justine's Hospital, Dalhousie University, Unity Health Toronto, University of Toronto, The Hospital for Sick Children, Maternal, Infant, Child and Youth Research Network (MICYRN)
Responsible party
Sponsor
First posted
Oct 13, 2023
Start date
Sep 16, 2024
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jul 27, 2026

Study contacts

Faiza Khawaja
Contact
fkhawaja@hollandbloorview.ca
4164256220 ext. 3526
Dr. Evdokia Anagnostou
principal investigator · Holland Bloorview Kids Rehab Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sertraline

Start the discussion